| Literature DB >> 33498945 |
Francisca Ferrer-Marín1,2,3, Ernesto José Cuenca-Zamora1, Pedro Jesús Guijarro-Carrillo3, Raúl Teruel-Montoya1,2.
Abstract
Thrombosis is a major cause of morbimortality in patients with chronic Philadelphia chromosome-negative myeloproliferative neoplasms (MPN). In the last decade, multiple lines of evidence support the role of leukocytes in thrombosis of MPN patients. Besides the increase in the number of cells, neutrophils and monocytes of MPN patients show a pro-coagulant activated phenotype. Once activated, neutrophils release structures composed of DNA, histones, and granular proteins, called extracellular neutrophil traps (NETs), which in addition to killing pathogens, provide an ideal matrix for platelet activation and coagulation mechanisms. Herein, we review the published literature related to the involvement of NETs in the pathogenesis of thrombosis in the setting of MPN; the effect that cytoreductive therapies and JAK inhibitors can have on markers of NETosis, and, finally, the novel therapeutic strategies targeting NETs to reduce the thrombotic complications in these patients.Entities:
Keywords: NETs; myeloproliferative neoplasms; neutrophils; thrombosis
Mesh:
Year: 2021 PMID: 33498945 PMCID: PMC7866001 DOI: 10.3390/ijms22031143
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923